Additionally, GLP-1R agonists inhibit tau protein hyperphosphorylation, promote the release of brain-derived neurotrophic factor, and reduce neuroinflammatory responses by inhibiting microglial and astrocyte activation [55,56,57]
Improves both insulin sensitivity and insulin secretion supporting better blood sugar regulation
Two primary areas emerge from the data as being critical for longevity: gut barrier integrity and metabolic function, especially as it relates to GLP-1
In short-bowel syndrome escalating throughout 4 weeks, the constant weight gain above preoperative values started immediately with peroral and parental BPC 157 therapy and the villus height, crypth depth and muscle thickness (inner (circular) muscular layer) additionally increased[3]
Mitoma, H., Hadjivassiliou, M